News|Articles|October 13, 2020

LabVantage Awarded US Army Contract for LIMS COVID-19 Vaccine Support

The company will supply its LIMS to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.

LabVantage Solutions, a provider of laboratory informatics solutions and services, announced on Oct. 13, 2020 that the US Army Medical Research Acquisition Activity has presented it with a contract to supply its LabVantage Pharma laboratory information management system (LIMS) to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.

According to a LabVantage press release, the company’s LIMS package for pharmaceutical and biotech laboratories comes with batch management, stability testing, consumables management, environmental monitoring, barcode label printing, instrument calibration, certification, and maintenance.

“We developed LabVantage Pharma to make it fast and easy for pharmaceutical and biotech organizations to acquire and implement a state-of-the-art laboratory information management system to enable efficient and compliant quality manufacturing,” said John Heiser, CEO of LabVantage, in the press release. “We appreciate that WRAIR understood the unique benefits of LabVantage Pharma and moved to expedite its acquisition via a sole source contract. We are very proud that our purpose-built LIMS is now helping the WRAIR address the urgent need for new vaccines and therapies to combat COVID-19 and other serious diseases.”

Source: LabVantage​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.